NCT07875036 Comparative Effects of Coherent Breathing and Regular Paced Breathing on Dyspnea and Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease
| NCT ID | NCT07875036 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Foundation University Islamabad |
| Condition | Pulmonary Disease, Chronic Obstructive (COPD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2026-02-11 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory condition of airways characterized by recurrent episodes of coughing, respiratory muscle weakness, lung hyperinflation and air trapping which ultimately leads to dyspnea, impaired pulmonary function and reduced quality of life. Non- pharmacological approaches, particularly breathing retraining techniques, have gained recognition as complementary strategies for optimizing COPD management by improving overall functional status and exercise tolerance in the patients.
Eligibility Criteria
Inclusion Criteria: * Age between 40-75 years. * Both genders (male and females). * Diagnosed COPD mild to moderate stage according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification: Mild: FEV1 ≥ 80% predicted Moderate: FEV1 fall between 50-79% * Diagnosed with COPD for at least 6 months prior to enrollment in study * Resting SpO₂ ≥ 90% on room air Exclusion Criteria: * Severe and very severe stage of COPD according to GOLD classification * Patients having acute exacerbation of COPD with in the last 4 weeks * Hemodnamically unstable patients * Current smokers (active smoking or individuals using any tobacco product within the 6 months) * Other sgnificant respiratory diseases (e.g., asthma, bronchiectasis, ILD, active tuberculosis) * Patients unable to follow commands/instructions * Patients currently participating in any other structured pulmonary rehabilitation or breathing intervention program
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07875036 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Pulmonary Disease, Chronic Obstructive (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07875036 currently recruiting?
Yes, NCT07875036 is actively recruiting participants. Contact the research team at hirawaqar7991@gmail.com for enrollment information.
Where is the NCT07875036 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT07875036 clinical trial?
NCT07875036 is sponsored by Foundation University Islamabad. The trial plans to enroll 46 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.